Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Indivior ( (INDV) ).
Indivior PLC announced its decision to cancel its secondary listing on the London Stock Exchange, maintaining its primary listing on Nasdaq. This strategic move aligns with the company’s focus on the U.S. market, where over 80% of its net revenue is generated, and aims to reduce costs and complexity associated with maintaining a secondary listing. The decision reflects the higher trading volume and shareholder base in the U.S., and is expected to streamline operations and enhance alignment with U.S. market peers.
More about Indivior
Indivior is a global pharmaceutical company focused on developing medicines to treat opioid use disorder (OUD). With a vision to provide evidence-based treatment for OUD worldwide, the company aims to transform OUD from a global crisis into a recognized and treated chronic disease. Headquartered in Richmond, VA, Indivior employs over 1,000 individuals globally and offers a portfolio of OUD treatments.
Learn more about INDV stock on TipRanks’ Stock Analysis page.